Literature DB >> 8909874

Topically applied halofuginone, an inhibitor of collagen type I transcription, reduces peritendinous fibrous adhesions following surgery.

M Nyska1, A Nyska, E Rivlin, S Porat, M Pines, S Shoshan, A Nagler.   

Abstract

To test in vivo the effect of previously observed inhibition of collagen type I transcription by the plant alkaloid Halofuginone, deep flexor tendons of 12 chickens were severed and sutured, and Halofuginone was applied topically at the site of surgery. Intact tendons, and severed but untreated tendons served as controls. The effect of the treatment was assessed by histological, biochemical, and biomechanical examinations of the operated and intact tendons three weeks after surgery. The results indicated an almost complete absence of fibrous peritendinous adhesions in the histologic sections of the Halofuginone treated tendons. There was a statistically significant decrease in collagen contents of and in both force and energy required to pull out the Halofuginone treated tendons from their sheath, relative to the untreated controls. Halofuginone had no effect on the cellularity of the healing tissue. We conclude that Halofuginone is a potent inhibitor of fibrous peritendinous adhesions with potentially important clinical applications.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8909874     DOI: 10.3109/03008209609021495

Source DB:  PubMed          Journal:  Connect Tissue Res        ISSN: 0300-8207            Impact factor:   3.417


  7 in total

1.  Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis.

Authors:  R Abramovitch; H Dafni; M Neeman; A Nagler; M Pines
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

2.  Antimalarial activities and therapeutic properties of febrifugine analogs.

Authors:  Suping Jiang; Qiang Zeng; Montip Gettayacamin; Anchalee Tungtaeng; Srisombat Wannaying; Apassorn Lim; Pranee Hansukjariya; Christopher O Okunji; Shuren Zhu; Daohe Fang
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  Halofuginone--an inhibitor of collagen type I synthesis--prevents postoperative formation of abdominal adhesions.

Authors:  A Nagler; A I Rivkind; J Raphael; F Levi-Schaffer; O Genina; I Lavelin; M Pines
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

4.  Efficacy of topical halofuginone in myringotomy patency.

Authors:  Taner Ozdemir; Hakan Cincik; Salim Dogru; I Engin Cekin; S Arif Ulubil; Atila Gungor
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-06-24       Impact factor: 2.503

5.  Halofuginone, a specific inhibitor of collagen type 1 synthesis, ameliorates oxidant colonic damage in rats with experimental colitis.

Authors:  Berna Karakoyun; Meral Yüksel; Feriha Ercan; Emine Salva; Işil Işik; Berrak C Yeğen
Journal:  Dig Dis Sci       Date:  2009-04-24       Impact factor: 3.199

6.  Prevention of Tendon Adhesions by ERK2 Small Interfering RNAs.

Authors:  Hongjiang Ruan; Shen Liu; Fengfeng Li; Xujun Li; Cunyi Fan
Journal:  Int J Mol Sci       Date:  2013-02-21       Impact factor: 5.923

7.  Improved tendon healing by a combination of Tanshinone IIA and miR-29b inhibitor treatment through preventing tendon adhesion and enhancing tendon strength.

Authors:  Haiying Zhou; Shuai Jiang; Pengfei Li; Hui Shen; Hu Yang; Shengquan Xu; Chenyi Ye; Mingjian Chen; Hui Lu
Journal:  Int J Med Sci       Date:  2020-04-27       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.